Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.
1. An FKBP52 binding molecule having a chemical structure of Formula II
wherein R 1 or R 2 are independently and separately selected from H, amino, nitro, halogen, F 5 S, F 3 C, or C1-C3 alkoxy, wherein R 1 and R 2 are not both H; R 3 is independently selected from H or C1-C3 alkyl; R 4 is independently selected from H, C1-C3 alkyl, C1-C3 alkoxy, or hydroxyl; R 5 is independently selected from H, halogen, or C1-C3 alkoxy; and R 6 is independently selected from H, halogen, hydroxyl, and C1-C3 alkoxy, wherein R 6 is not C1 alkoxy, when R 1 or R 2 is chlorine, R 4 is C1 alkoxy and R 5 is hydrogen; and R 5 is not C1 alkoxy when R 1 or R 2 is chlorine, R 4 is C1 alkoxy, and R 6 is hydrogen.
2. The molecule of claim 1 , wherein R 1 , R 2 , R 5 , or R 6 is independently selected from H, F, Cl, or I.
3. The molecule of claim 1 , wherein R 1 , R 2 , R 5 , or R 6 is independently F.
4. A method of treating prostate cancer comprising administering an effective amount of the compound of claim 1 to a subject having prostate cancer.